FDA flags rare optic nerve damage risk in diabetes/weight drugs after trial review

FDA review of 126 clinical trials found a rare but serious optic nerve condition (NAION) occurring more frequently with certain diabetes and weight-loss medications. The agency has not issued a formal restriction, and causality remains unconfirmed. This could affect prescribing patterns and liability exposure for drugmakers.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works